{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T01:04:09Z","timestamp":1778720649371,"version":"3.51.4"},"reference-count":49,"publisher":"Elsevier BV","issue":"51","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation","doi-asserted-by":"crossref","award":["30672464"],"award-info":[{"award-number":["30672464"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"College Students Innovation Project for the R&D of Novel Drugs","award":["J1310032"],"award-info":[{"award-number":["J1310032"]}]},{"name":"College Students Innovation Project for the R&D of Novel Drugs","award":["J1030830"],"award-info":[{"award-number":["J1030830"]}]},{"name":"Priority Academic Program Development of Jiangsu Higher Education Institutions [PAPD]","award":["KYZZ16_0422"],"award-info":[{"award-number":["KYZZ16_0422"]}]},{"name":"Priority Academic Program Development of Jiangsu Higher Education Institutions [PAPD]","award":["KYZZ_0191"],"award-info":[{"award-number":["KYZZ_0191"]}]},{"name":"Research Innovation Program for Graduates of Jiangsu Province","award":["PPZY2015A057"],"award-info":[{"award-number":["PPZY2015A057"]}]},{"name":"Jiangsu Higher Education Institutions"},{"name":"National Undergraduate Training Programs for Innovation and Entrepreneurship"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.vaccine.2017.10.035","type":"journal-article","created":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T02:00:42Z","timestamp":1511316042000},"page":"7187-7197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Construction of a novel vaccine by conjugating a B-cell epitope of DPP4 to peptide IA2(5)-P2-1 to significantly control type 1 diabetes in NOD mice"],"prefix":"10.1016","volume":"35","author":[{"given":"Ya","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huimin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiping","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhixin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoran","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanjie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiali","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9277","key":"10.1016\/j.vaccine.2017.10.035_b0005","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0140-6736(01)05415-0","article-title":"Type 1 diabetes: new perspectives on disease pathogenesis and treatment","volume":"358","author":"Atkinson","year":"2001","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vaccine.2017.10.035_b0010","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0092-8674(00)81106-X","article-title":"Insulin-dependent diabetes mellitus","volume":"85","author":"Tisch","year":"1996","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.vaccine.2017.10.035_b0015","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-2249.2007.03328.x","article-title":"Translational mini-review series on type 1 diabetes: Immune-based therapeutic approaches for type 1 diabetes","volume":"148","author":"Staeva-Vieira","year":"2007","journal-title":"Clin Exp Immunol"},{"issue":"59","key":"10.1016\/j.vaccine.2017.10.035_b0020","first-page":"293","article-title":"Autoantigen based vaccines for type 1 diabetes","volume":"11","author":"Nicholas","year":"2011","journal-title":"Discov Med"},{"issue":"8","key":"10.1016\/j.vaccine.2017.10.035_b0025","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1210\/jc.2003-031887","article-title":"Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY)","volume":"89","author":"Barker","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.vaccine.2017.10.035_b0030","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.2337\/db10-0630","article-title":"Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential","volume":"59","author":"Peakman","year":"2010","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.vaccine.2017.10.035_b0035","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/(SICI)1099-0895(199712)13:4<247::AID-DMR196>3.0.CO;2-V","article-title":"Diabetes registries and early biological markers of insulin-dependent diabetes mellitus. Belgian Diabetes Registry","volume":"13","author":"Gorus","year":"1997","journal-title":"Diabetes Metab Rev"},{"issue":"8","key":"10.1016\/j.vaccine.2017.10.035_b0040","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.2337\/diab.46.8.1270","article-title":"Value of antibodies to islet protein tyrosine phosphatase-like molecule in predicting type 1 diabetes","volume":"46","author":"Hawa","year":"1997","journal-title":"Diabetes"},{"issue":"9","key":"10.1016\/j.vaccine.2017.10.035_b0045","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.numecd.2008.08.002","article-title":"Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk","volume":"18","author":"Mannucci","year":"2008","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2017.10.035_b0050","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1365-2710.2012.01342.x","article-title":"Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes","volume":"37","author":"Cornell","year":"2012","journal-title":"J Clin Pharm Ther"},{"issue":"12","key":"10.1016\/j.vaccine.2017.10.035_b0055","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.2337\/dc06-0703","article-title":"Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes","volume":"29","author":"Aschner","year":"2006","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.vaccine.2017.10.035_b0060","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s12325-009-0030-9","article-title":"Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes","volume":"26","author":"Deacon","year":"2009","journal-title":"Adv Ther"},{"issue":"2","key":"10.1016\/j.vaccine.2017.10.035_b0065","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1124\/jpet.105.087064","article-title":"Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats","volume":"315","author":"Burkey","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"10.1016\/j.vaccine.2017.10.035_b0070","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.tips.2009.08.003","article-title":"Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?","volume":"30","author":"Yazbeck","year":"2009","journal-title":"Trends Pharmacol Sci"},{"issue":"11","key":"10.1016\/j.vaccine.2017.10.035_b0075","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.amjcard.2012.01.398","article-title":"Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors","volume":"109","author":"Chrysant","year":"2012","journal-title":"Am J Cardiol"},{"issue":"11\u201312","key":"10.1016\/j.vaccine.2017.10.035_b0080","first-page":"1093","article-title":"Serum dipeptidyl peptidase 4 activity in children with type 1 diabetes mellitus","volume":"26","author":"Iwabuchi","year":"2013","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.vaccine.2017.10.035_b0085","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.bmcl.2005.01.020","article-title":"Synthesis and evaluation of pyrazolidine derivatives as dipeptidyl peptidase IV (DP-IV) inhibitors","volume":"15","author":"Ahn","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.vaccine.2017.10.035_b0090","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1124\/jpet.105.087064","article-title":"Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats","volume":"315","author":"Burkey","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.vaccine.2017.10.035_b0095","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.tips.2009.08.003","article-title":"Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?","volume":"30","author":"Yazbeck","year":"2009","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.vaccine.2017.10.035_b0100","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.amjcard.2012.01.398","article-title":"Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors","volume":"109","author":"Chrysant","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.vaccine.2017.10.035_b0105","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1515\/jpem-2013-0122","article-title":"Serum dipeptidyl peptidase 4 activity in children with type 1 diabetes mellitus","volume":"26","author":"Iwabuchi","year":"2013","journal-title":"J Pediatr Endocrinol Metab"},{"key":"10.1016\/j.vaccine.2017.10.035_b0110","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2337\/db07-1639","article-title":"Inhibition of dipeptidyl peptidase IV with sitagliptin (MK0431) prolongs islet graft survival in streptozotocin-induced diabetic mice","volume":"57","author":"Kim","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.vaccine.2017.10.035_b0115","doi-asserted-by":"crossref","first-page":"641","DOI":"10.2337\/db08-1101","article-title":"Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation","volume":"58","author":"Kim","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.vaccine.2017.10.035_b0120","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1210\/en.2010-0068","article-title":"Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor","volume":"151","author":"Tian","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.vaccine.2017.10.035_b0125","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1007\/s00125-009-1390-z","article-title":"Rabinovitch Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice","volume":"52","author":"Suarez-Pinzon","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.vaccine.2017.10.035_b0130","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1007\/s00125-012-2723-x","article-title":"Treatment of autoimmune diabetes in NOD mice by Toll-like receptor 2 tolerance in conjunction with dipeptidyl peptidase 4 inhibition","volume":"55","author":"Kim","year":"2012","journal-title":"Diabetologia"},{"key":"10.1016\/j.vaccine.2017.10.035_b0135","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.2337\/db08-0688","article-title":"Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice","volume":"57","author":"Suarez-Pinzon","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.vaccine.2017.10.035_b0140","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1046\/j.1365-2249.2000.01352.x","article-title":"Mapping of novel autoreactive epitopes of the diabetes-associated autoantigen IA-2","volume":"122","author":"Seissler","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2017.10.035_b0150","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/S0140-6736(01)06801-5","article-title":"Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial","volume":"358","author":"Raz","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2017.10.035_b0155","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s10529-009-9963-y","article-title":"A new screening method based on yeast-expressed human dipeptidyl peptidase IV and discovery of novel inhibitors","volume":"31","author":"Hu","year":"2009","journal-title":"Biotech Lett"},{"key":"10.1016\/j.vaccine.2017.10.035_b0160","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.intimp.2016.03.024","article-title":"Fusion protein His-Hsp65-6IA2P2 prevents type 1 diabetes through nasal immunization in NOD Mice","volume":"35","author":"Lu","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.vaccine.2017.10.035_b0165","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1073\/pnas.88.8.3088","article-title":"Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein","volume":"88","author":"Elias","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2017.10.035_b0170","doi-asserted-by":"crossref","first-page":"626","DOI":"10.2337\/diab.44.6.626","article-title":"Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM","volume":"44","author":"Dupre","year":"1995","journal-title":"Diabetes"},{"key":"10.1016\/j.vaccine.2017.10.035_b0175","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/j.1464-5491.2011.03331.x","article-title":"Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial","volume":"28","author":"Ellis","year":"2011","journal-title":"Diabet Med"},{"key":"10.1016\/j.vaccine.2017.10.035_b0180","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.arcmed.2013.03.004","article-title":"Vildagliptin ameliorates oxidative stress and pancreatic beta cell destruction in type 1 diabetic rats","volume":"44","author":"Avila Dde","year":"2013","journal-title":"Arch Med Res"},{"key":"10.1016\/j.vaccine.2017.10.035_b0185","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1055\/s-0034-1371892","article-title":"Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis","volume":"46","author":"Nakashima","year":"2014","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.vaccine.2017.10.035_b0190","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/sj.icb.7100151","article-title":"Vaccination against self to prevent autoimmune disease: the type 1 diabetes model","volume":"86","author":"Harrison","year":"2008","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.vaccine.2017.10.035_b0195","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/nbt1098-934","article-title":"A plant-based cholera toxin B subunit-insulin fusion protein protects against the development of autoimmune diabetes","volume":"16","author":"Arakawa","year":"1998","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.vaccine.2017.10.035_b0200","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1016\/j.vaccine.2010.02.100","article-title":"Jingjing HSP65 serves as an immunogenic carrier for a diabetogenic peptide P277 inducing anti-inflammatory immune response in NOD mice by nasal administration","volume":"28","author":"Liang","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.10.035_b0205","doi-asserted-by":"crossref","first-page":"E1256","DOI":"10.1073\/pnas.1322009111","article-title":"Therapeutic vaccine against DPP4 improves glucose metabolism in mice","volume":"111","author":"Pang","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2017.10.035_b0210","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2337\/diabetes.52.3.741","article-title":"Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats","volume":"52","author":"Pospisilik","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.vaccine.2017.10.035_b0215","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1254\/jphs.FP0061376","article-title":"Comparison of efficacies of a dipeptidyl peptidase IV inhibitor and alpha-glucosidase inhibitors in oral carbohydrate and meal tolerance tests and the effects of their combination in mice","volume":"104","author":"Yamazaki","year":"2007","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.vaccine.2017.10.035_b0220","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1210\/endo.142.2.7983","article-title":"Minireview: the glucagon-like peptides","volume":"142","author":"Drucker","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.vaccine.2017.10.035_b0225","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/sj.bmt.1703305","article-title":"A patient with anaphylactoid hypersensitivity to intravenous cyclosporine and subcutaneous phytonadione (vitamin K(1))","volume":"28","author":"Riegert-Johnson","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.vaccine.2017.10.035_b0230","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.2174\/138161211798157531","article-title":"Clinical update on the use of immuno modulators (antiCD3, GAD, Diapep277, anti-IL1) in type 1 diabetes","volume":"17","author":"Pozzilli","year":"2011","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.vaccine.2017.10.035_b0235","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.2337\/db13-1236","article-title":"Oral delivery of glutamic acid decarboxylase (GAD)-65 and IL10 by Lactococcus lactis reverses diabetes in recent-onset NOD mice","volume":"63","author":"Robert","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.vaccine.2017.10.035_b0240","doi-asserted-by":"crossref","first-page":"e54712","DOI":"10.1371\/journal.pone.0054712","article-title":"Transient B-cell depletion with anti-CD20 in combination with proinsulin DNA vaccine or oral insulin: immunologic effects and efficacy in NOD mice","volume":"8","author":"Sarikonda","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2017.10.035_b0245","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMoa1107096","article-title":"GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus","volume":"366","author":"Ludvigsson","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.10.035_b0145","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.intimp.2011.04.012","article-title":"Vaccination of non-obese diabetic mice with a fragment of peptide P277 attenuates insulin-dependent diabetes mellitus","volume":"11","author":"Ma","year":"2011","journal-title":"Int Immunopharmacol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17314433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17314433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T14:53:41Z","timestamp":1543244021000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17314433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":49,"journal-issue":{"issue":"51","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0264410X17314433"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.10.035","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Construction of a novel vaccine by conjugating a B-cell epitope of DPP4 to peptide IA2(5)-P2-1 to significantly control type 1 diabetes in NOD mice","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.10.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}